Loading…
Chinese leader in companion-diagnostic tests that identify gene mutations to guide targeted cancer therapy.
Chinese leader in companion-diagnostic tests that identify gene mutations to guide targeted cancer therapy.
Sells reagent kits that hospitals and labs use up one test at a time, so revenue follows the number of cancer patients tested rather than equipment purchases. Many kits are approved by China's drug regulator alongside specific targeted drugs, so a new drug approval can create demand for a matching test.
In one line: A Chinese Foundation Medicine/QIAGEN for companion diagnostics.
Moat: narrow (regulatory licence, IP / patents). Companion-diagnostic approvals tied to specific approved cancer drugs create lock-in.
Headquarters: Xiamen, Fujian, China · Founded: 2003 · Employees: 1,175
Size Amoy Diagnostics (300685.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.10B, the 2113th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥19.08 on 6 Nov 2026.
Performance Over six months the shares fell 14.2%, against -3.6% for the median peer and -16.4% for the China market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue grew 6.7% over the last twelve months (peer median +13.7%); the operating margin is 33.8% (peer median 7.2%).
Valuation It trades at 20.9× forward earnings against a peer median of 27.0× (6th cheapest of 12).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -4 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 29.6 points above its cost of capital (8.7% WACC).
Next results Next results expected around 13 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.20B | CN¥1.19B | CN¥1.11B | CN¥1.04B | CN¥840M |
| Revenue growth | — | +7% | +6% | +24% | — |
| Gross profit | CN¥988M | CN¥931M | CN¥889M | CN¥825M | CN¥651M |
| EBITDA | n/a | CN¥420M | CN¥334M | CN¥328M | CN¥196M |
| Net income | CN¥346M | CN¥361M | CN¥255M | CN¥261M | CN¥264M |
| Free cash flow | CN¥346M | CN¥311M | CN¥316M | CN¥261M | CN¥80.9M |
| Capital expenditure | CN¥60.2M | CN¥70.2M | CN¥40.2M | CN¥44.9M | CN¥78.3M |
| Total debt | CN¥168M | CN¥124M | CN¥91.6M | CN¥108M | CN¥53.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Amoy Diagnostics 300685.SZ | $1.10B | -14% | +7% | 34% | 20.9× | 6.5% |
| Qiagen QGEN | $10.4B | +52% | +3% | 25% | 19.8× | 8.8% |
| Brenntag BNR.DE | $10.0B | 0% | -5% | 5% | 14.5× | 1.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300685.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.4% | +1.2% | 5th lowest of 21 |
| 6-month return | -14.2% | -3.6% | 9th lowest of 20 |
| Distance from 52-week high | -20.9% | -35.4% | 6th highest of 21 |
| Revenue growth (TTM) | +6.7% | +13.7% | 9th lowest of 20 |
| Operating margin | 33.8% | 7.2% | 2nd highest of 20 |
| Forward P/E | 20.9× | 27.0× | 6th cheapest of 12 |
| Growth the price implies (Req g, 7 yrs) | 6.5% | 10.0% | 4th least demanding of 10 |
| Growth delivered (Del g) | +10.3% | +8.6% | 3rd highest of 10 |
| Hurdle (Req g minus delivered) | -3.8 pp | +1.3 pp | 3rd least demanding of 10 |
| ROIC minus cost of capital | +29.6 pp | -5.8 pp | 2nd highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Amoy Diagnostics 300685.SZ | China | $1.10B | -14% | +7% | 34% | 20.9× | 6.5% | +10.3% |
| IRadimed IRMD | United States | $1.10B | 0% | +11% | 32% | 36.0× | 19.1% | +21.5% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.11B | -27% | -11% | -33% | n/a | n/a | n/a |
| Freenome FRNM | United States | $1.09B | n/a | n/a | n/a | n/a | n/a | n/a |
| SI-BONE SIBN | United States | $1.09B | +98% | +14% | -8% | n/a | n/a | n/a |
| PHC 6523.T | Japan | $1.09B | +36% | +3% | 7% | 7.9× | -2.3% | +3.6% |
| Tinavi Medical Technologies 688277.SS | China | $1.08B | -30% | -2% | -59% | n/a | n/a | n/a |
| INKON Life Technology 300143.SZ | China | $1.08B | -14% | +22% | 12% | 55.2× | 12.4% | +12.9% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | +1% | -4% | 36% | 18.2× | 1.5% | +9.9% |
| L&C BIO 290650.KS | South Korea | $1.07B | -17% | +53% | 17% | 213.2× | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.14B | +6% | +14% | 25% | 33.7× | 10.0% | +8.8% |
| Alphatec ATEC | United States | $1.15B | -1% | +15% | -3% | 15.0× | n/a | n/a |
| Edan Instruments 300206.SZ | China | $1.05B | -19% | +14% | 17% | 18.8× | 7.7% | -2.9% |
| Inno Laser Technology 301021.SZ | China | $1.16B | -18% | +17% | 9% | n/a | 53.9% | +8.6% |
| Integra LifeSciences IART | United States | $1.04B | -4% | +1% | 12% | 5.8× | 5.2% | +3.6% |
| Tandem Diabetes Care TNDM | United States | $1.18B | +9% | +4% | -4% | n/a | n/a | n/a |
| Ceribell CBLL | United States | $1.03B | +32% | +31% | -70% | n/a | n/a | n/a |
| PROCEPT BioRobotics PRCT | United States | $1.18B | -19% | +23% | -34% | n/a | n/a | n/a |
| Castle Biosciences CSTL | United States | $993M | +64% | +3% | -9% | n/a | n/a | n/a |
| Artivion AORT | United States | $985M | -20% | +16% | 7% | 3,912.9× | n/a | n/a |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.24B | -25% | -6% | 18% | 27.0× | 12.7% | -3.5% |